Alnylam Pharmaceuticals, Inc. $ALNY Stock Sold by Robeco Institutional Asset Management B.V.

Key Points

• Robeco Institutional Asset Management cut its Alnylam position by 92.4% in the third quarter, selling 173,744 shares and retaining 14,340 shares valued at approximately $3.5 million. Institutional investors collectively own 92.97% of the company.
• Alnylam reported quarterly earnings of $1.84 per share, beating estimates of $1.63, while revenue rose 66.9% year over year to $1.29 billion. The stock opened at $224.03, well below its 200-day moving average of $270.61 and its 12-month high of $485.36.
• Analysts remain generally bullish, with a consensus “Moderate Buy” rating and an average price target of $364.95. Recent Phase 1b data for Huntington’s disease candidate brezosiran showed approximately 60%–64% mutant huntingtin reduction, though the program remains early-stage and carries clinical execution risks.

Robeco Institutional Asset Management B.V. trimmed its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 92.4% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 14,340 shares of the biopharmaceutical company's stock after selling 173,744 shares during the period. Robeco Institutional Asset Management B.V.'s holdings in Alnylam Pharmaceuticals were worth $3,538,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. Toth Financial Advisory Corp acquired a new position in Alnylam Pharmaceuticals in the third quarter valued at $25,000. Burkett Financial Services LLC purchased a new stake in Alnylam Pharmaceuticals during the third quarter valued at about $37,000. CoreCap Advisors LLC increased its stake in Alnylam Pharmaceuticals by 744.4% during the third quarter. CoreCap Advisors LLC now owns 152 shares of the biopharmaceutical company's stock worth $38,000 after acquiring an additional 134 shares during the last quarter. Keating Financial Advisory Services Inc. acquired a new stake in Alnylam Pharmaceuticals during the second quarter worth about $42,000. Finally, Ascentis Independent Advisors acquired a new stake in Alnylam Pharmaceuticals during the first quarter worth about $64,000. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY opened at $224.03 on Monday. The business's 50-day moving average is $239.80 and its two-hundred day moving average is $270.61. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.05 and a quick ratio of 2.99. Alnylam Pharmaceuticals, Inc. has a 12 month low of $197.81 and a 12 month high of $485.36. The firm has a market capitalization of $29.98 billion, a PE ratio of 41.64 and a beta of 0.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, topping the consensus estimate of $1.63 by $0.21. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%. The company had revenue of $1.29 billion during the quarter, compared to the consensus estimate of $1.32 billion. During the same quarter in the prior year, the business earned ($0.51) earnings per share. The company's revenue was up 66.9% compared to the same quarter last year. Research analysts predict that Alnylam Pharmaceuticals, Inc. will post 6.43 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP Bryan Supran sold 1,758 shares of the business's stock in a transaction that occurred on Friday, October 2nd. The stock was sold at an average price of $226.88, for a total transaction of $398,855.04. Following the transaction, the executive vice president directly owned 12,807 shares of the company's stock, valued at approximately $2,905,652.16. The trade was a 12.07% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 0.86% of the company's stock.

Alnylam Pharmaceuticals News Roundup

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Promising Huntington’s disease results: Alnylam reported that investigational RNAi therapy brezosiran (ALN-HTT02) reduced mutant huntingtin by approximately 60% to 64% in an initial Phase 1b study. The company described the reduction as deep and durable, potentially supporting further development in a disease with significant unmet medical need. Alnylam brezosiran Phase 1b results
• Positive Sentiment: Potential pipeline expansion: Reports characterized brezosiran’s huntingtin knockdown as potentially best-in-class, and Alnylam plans to advance the program toward a pivotal trial. Success could broaden the company’s long-term growth beyond its marketed RNAi medicines. Alnylam plans pivotal Huntington’s trial
• Positive Sentiment: Analyst confidence remains strong: Raymond James reiterated its Strong Buy rating on ALNY. Separately, the reported consensus price target is $364.95, substantially above the level described in the provided market background. Raymond James Strong Buy rating
• Neutral Sentiment: Earnings expectations are favorable but unconfirmed: Zacks expects Alnylam to have a favorable setup for an earnings beat in its upcoming report. However, this is only an estimate and does not yet represent reported results. Alnylam earnings expectations
• Negative Sentiment: Clinical and valuation risks remain: Brezosiran is still in Phase 1b, so its efficacy, safety, durability and ability to succeed in a pivotal trial remain uncertain. The stock also trades well below its 200-day moving average, suggesting investors may still be discounting execution, development and valuation risks.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on ALNY shares. Sanford C. Bernstein restated a "buy" rating on shares of Alnylam Pharmaceuticals in a report on Monday, August 31st. Weiss Ratings upgraded Alnylam Pharmaceuticals from a "hold (c-)" rating to a "hold (c)" rating in a report on Friday, July 31st. TD Cowen reissued a "buy" rating on shares of Alnylam Pharmaceuticals in a research report on Monday, August 31st. Needham & Company LLC dropped their target price on shares of Alnylam Pharmaceuticals from $510.00 to $357.00 and set a "buy" rating for the company in a research report on Thursday, July 30th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $455.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday, September 21st. Four equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $364.95.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company's therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam's marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.